5.41
price down icon0.37%   -0.02
after-market Dopo l'orario di chiusura: 5.42 0.010 +0.18%
loading
Precedente Chiudi:
$5.43
Aprire:
$5.43
Volume 24 ore:
127.41K
Relative Volume:
0.23
Capitalizzazione di mercato:
$239.18M
Reddito:
-
Utile/perdita netta:
$-32.74M
Rapporto P/E:
-6.5976
EPS:
-0.82
Flusso di cassa netto:
$-24.89M
1 W Prestazione:
-0.37%
1M Prestazione:
+3.84%
6M Prestazione:
-47.42%
1 anno Prestazione:
-58.03%
Intervallo 1D:
Value
$5.41
$5.45
Intervallo di 1 settimana:
Value
$5.41
$5.47
Portata 52W:
Value
$3.18
$16.02

Third Harmonic Bio Inc Stock (THRD) Company Profile

Name
Nome
Third Harmonic Bio Inc
Name
Telefono
(209) 727-2457
Name
Indirizzo
1700 MONTGOMERY STREET, SAN FRANCISCO
Name
Dipendente
31
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-26
Name
Ultimi documenti SEC
Name
THRD's Discussions on Twitter

Confronta THRD con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
THRD
Third Harmonic Bio Inc
5.41 239.18M 0 -32.74M -24.89M -0.82
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-28 Downgrade Stifel Buy → Hold
2025-02-12 Downgrade Morgan Stanley Overweight → Equal-Weight
2025-02-11 Downgrade Raymond James Outperform → Mkt Perform
2024-08-09 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2024-06-18 Iniziato Stifel Buy
2024-06-07 Iniziato Raymond James Outperform
2022-12-16 Downgrade Jefferies Buy → Hold
2022-12-15 Downgrade Morgan Stanley Overweight → Equal-Weight
2022-10-10 Iniziato Cowen Outperform
2022-10-10 Iniziato Jefferies Buy
2022-10-10 Iniziato Morgan Stanley Overweight
Mostra tutto

Third Harmonic Bio Inc Borsa (THRD) Ultime notizie

pulisher
Jun 16, 2025

Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace

Jun 16, 2025
pulisher
Jun 13, 2025

AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans - BioPharma Dive

Jun 13, 2025
pulisher
Jun 13, 2025

Third Harmonic Bio stockholders approve liquidation plan, set distribution By Investing.com - Investing.com India

Jun 13, 2025
pulisher
Jun 12, 2025

Finance Watch: Insmed Cashes In On Positive Data With $750m Offering - insights.citeline.com

Jun 12, 2025
pulisher
Jun 12, 2025

THRD Stockholders Approve Liquidation Plan with Initial Payouts Expected | THRD Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Third Harmonic Bio receives stockholder approval of plan of liquidation - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Third Harmonic Bio reports updated THB335 data, initiates THB335 sale - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

ADC Therapeutics reveals layoffs, $100M PIPE; Third Harmonic seeks buyer for asset - Endpoints News

Jun 12, 2025
pulisher
Jun 12, 2025

Third Harmonic Bio To Dissolve; THB335 Shows Promise, Sale Process Now Underway - Nasdaq

Jun 12, 2025
pulisher
Jun 12, 2025

Third Harmonic Bio stockholders approve liquidation plan, set distribution - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Third Harmonic Bio Approves Liquidation and Dissolution Plan - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

THRD Advances THB335 to Phase 2 Trials with Positive Phase 1 Results | THRD Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335 - The Manila Times

Jun 12, 2025
pulisher
Jun 12, 2025

Third Harmonic Bio Shareholders Win Big: $5.35/Share Payout Approved as Drug Shows 85% Efficacy - Stock Titan

Jun 12, 2025
pulisher
Jun 11, 2025

Third Harmonic Bio Approves Key Proposals at Annual Meeting - TipRanks

Jun 11, 2025
pulisher
Jun 06, 2025

At a crossroads, biotechs are passing on reverse mergers in 2025 - Endpoints News

Jun 06, 2025
pulisher
Jun 05, 2025

Fierce Biotech Layoff Tracker 2025: Rapt reduces workforce; Plexium pares down staff - Fierce Biotech

Jun 05, 2025
pulisher
May 30, 2025

Third Harmonic Bio Reports Q1 2025 Financial Results - TipRanks

May 30, 2025
pulisher
May 28, 2025

Cancer drugmaker iTeos to shut down - BioPharma Dive

May 28, 2025
pulisher
May 16, 2025

It’s been three months without a biotech IPO - Endpoints News

May 16, 2025
pulisher
May 08, 2025

THIRD HARMONIC BIO Earnings Results: $THRD Reports Quarterly Earnings - Nasdaq

May 08, 2025
pulisher
May 08, 2025

Third Harmonic Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 08, 2025
pulisher
May 05, 2025

Third Harmonic Bio Announces Plan of Liquidation and Dissolution - ADVFN

May 05, 2025
pulisher
May 02, 2025

Here’s Why Third Harmonic Bio (THRD) Fell in Q1 - Insider Monkey

May 02, 2025
pulisher
Apr 29, 2025

Acelyrin should liquidate instead of merging with Alumis, investor says - BioPharma Dive

Apr 29, 2025
pulisher
Apr 27, 2025

Third Harmonic Bio’s CSO Christopher Dinsmore Steps Down - MSN

Apr 27, 2025
pulisher
Apr 23, 2025

Third Harmonic Bio CSO steps down, enters separation agreement - Investing.com Australia

Apr 23, 2025
pulisher
Apr 23, 2025

Third Harmonic Bio Plans Liquidation With Lucrative Payouts - Finimize

Apr 23, 2025
pulisher
Apr 22, 2025

Third Harmonic Bio CSO steps down, enters separation agreement By Investing.com - Investing.com South Africa

Apr 22, 2025
pulisher
Apr 21, 2025

Dupixent bounces back in treating hives with FDA approval - BioWorld MedTech

Apr 21, 2025
pulisher
Apr 18, 2025

New fund Alis offers struggling biotechs an off-ramp: Finance Report - BioCentury

Apr 18, 2025
pulisher
Apr 17, 2025

Finance Watch: Investors Push ESSA Pharma, Elevation Oncology To Wind Down - insights.citeline.com

Apr 17, 2025
pulisher
Apr 16, 2025

SF biotech company, once worth nearly $1 billion, plans to shut down - SFGATE

Apr 16, 2025
pulisher
Apr 16, 2025

Biotech Alert: Searches spiking for these stocks today - TipRanks

Apr 16, 2025
pulisher
Apr 16, 2025

Third Harmonic Bio (THRD) Plans Liquidation; Significant Search Surge in Biotech Sector | ARTL Stock News - GuruFocus

Apr 16, 2025
pulisher
Apr 15, 2025

Third Harmonic Bio (THRD) Seeks Stockholder Approval for Liquida - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Third Harmonic Bio plans to liquidate the company, sell urticaria treatment - MSN

Apr 15, 2025
pulisher
Apr 15, 2025

Third Harmonic Bio, Inc. Liquidation and Shareholder Distribution: Analyst Maintains Hold Rating Amid Strategic Uncertainties - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

Third Harmonic's shutdown, Coherus and Xoma drug sales connectedBizwomen - The Business Journals

Apr 15, 2025
pulisher
Apr 15, 2025

Third Harmonic Bio leaps as it reveals liquidation plan - The Pharma Letter

Apr 15, 2025
pulisher
Apr 15, 2025

Big moves by small biotechs signal potential shift for investorsSan Francisco Business Times - The Business Journals

Apr 15, 2025
pulisher
Apr 15, 2025

Top 3 Health Care Stocks You May Want To Dump This Quarter - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Third Harmonic Bio Announces Liquidation Plan: Stock Skyrockets 39% Pre-Market, But Retail’s Shattered - MSN

Apr 15, 2025
pulisher
Apr 14, 2025

$26bn Brighton Jones hires new CFO - Citywire

Apr 14, 2025
pulisher
Apr 14, 2025

Third Harmonic Bio plans liquidation and asset sale By Investing.com - Investing.com South Africa

Apr 14, 2025

Third Harmonic Bio Inc Azioni (THRD) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Third Harmonic Bio Inc Azioni (THRD) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Conner Edward R.
Chief Medical Officer
Nov 08 '24
Sale
15.00
2,117
31,755
0
BVF PARTNERS L P/IL
See Explanation of Responses
Oct 29 '24
Sale
14.30
1,000,000
14,300,000
176,692
Conner Edward R.
Chief Medical Officer
Oct 28 '24
Option Exercise
4.20
2,673
11,227
2,673
Conner Edward R.
Chief Medical Officer
Oct 28 '24
Sale
15.00
2,673
40,095
0
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Capitalizzazione:     |  Volume (24 ore):